Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

For patients with bone metastases, high N‐telopeptide of type I collagen (NTX) levels correlate with increased risks of skeletal‐related events and death. However, the relation between NTX decreases and clinical benefits is unclear.

[1]  R. Cook,et al.  Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. , 2007, The oncologist.

[2]  R. Eastell,et al.  Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Howell,et al.  Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.

[4]  L. Demers,et al.  Bone markers in the management of metastatic bone disease. , 2001, Cancer treatment reviews.

[5]  K. Weinfurt,et al.  Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone Lesions , 2004, Medical care.

[6]  A. Lipton,et al.  Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma , 2003, Cancer.

[7]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[8]  G. Hortobagyi,et al.  Markers of bone resorption in patients treated with pamidronate. , 1998, European journal of cancer.

[9]  Bo Xu,et al.  [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases]. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.

[10]  K. Anstrom,et al.  Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer , 2006, Supportive Care in Cancer.

[11]  A. Lipton.  Bisphosphonate therapy in the oncology setting , 2003, Expert opinion on emerging drugs.

[12]  L. Vlahos,et al.  Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline , 2005, Medical Oncology.

[13]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[14]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[15]  L. Demers,et al.  Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Coleman.  Emerging strategies in bone health management for the adjuvant patient. , 2007, Seminars in oncology.

[17]  T. Economopoulos,et al.  Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. , 2005, Anticancer research.

[18]  R. Cook,et al.  Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical Endpoints , 2002, American journal of clinical oncology.

[19]  F. Saad,et al.  Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Saad,et al.  615 Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases , 2004 .

[21]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[22]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[23]  Jonathan R. Green.  Bisphosphonates: preclinical review. , 2004, The oncologist.

[24]  F. Saad,et al.  Pathologic fractures correlate with reduced survival in patients with malignant bone disease , 2007, Cancer.

[25]  M. Caraglia,et al.  Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.

[26]  M. Resnick,et al.  Skeletal fractures negatively correlate with overall survival in men with prostate cancer. , 2002, The Journal of urology.

[27]  T. Tanvetyanon.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2005, Cancer.

[28]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[29]  F. Saad,et al.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.

[30]  T. Evrensel,et al.  Evaluation of lung cancer metastases to the spine. , 2006, Acta orthopaedica Belgica.

[31]  R. Coleman.  The clinical use of bone resorption markers in patients with malignant bone disease , 2002, Cancer.

[32]  M. Krzakowski,et al.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Costa,et al.  P141 Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate , 2007 .

[34]  B. Drinkwater,et al.  Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. , 1997, The American journal of medicine.